Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25044821 | 0.94 | L3MBTL3 (0.33) | OPRM1HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL14197801 | 0.74 | SLC18A3 (0.37) | OPRM1 | |
| SCHEMBL25043774 | 0.72 | TSHR (0.31) | — | |
| SCHEMBL14811046 | 0.68 | HTR6 (0.43) | HTR6CHRNA7 | |
| SCHEMBL15189276 | 0.67 | KDM4E (0.34) | — | |
| SCHEMBL29112097 | 0.63 | — | — | |
| SCHEMBL14754059 | 0.62 | HTR2C (0.38) | HTR6 | |
| SCHEMBL24210948 | 0.62 | JUN (0.30) | — | |
| SCHEMBL15189282 | 0.61 | HIF1A (0.37) | HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL499482 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| US-8097643-B2 | Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | LABORATORIOS DEL DR. ESTEVE S. A. (ES) | 2012-01-17 | — | — | US | disclosed |
| EP-1648443-B1 | 1-SULFONYLINDOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS 5-HT6 LIGANDS | ESTEVE LABOR DR (ES) | 2010-07-14 | — | — | EP | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| US-7655690-B2 | 1-sulfonylindole derivatives, their preparation and their use as 5-HT6 ligands | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2010-02-02 | — | — | US | disclosed |
| US-20070185158-A1 | Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-08-09 | — | — | US | disclosed |
| US-20070185207-A1 | Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | LABORATORIOS DEL DR ESTEVE S.A (ES) | 2007-08-09 | — | — | US | disclosed |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| US-20070060581-A1 | 1-Sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| US-20070060581-A1 | 1-Sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| US-20070043041-A1 | Indol-6 sulfonamide derivative, their preparation and their use 5-ht-6 as modulators | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-22 | — | — | US | disclosed |
| US-20070032520-A1 | Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-02-08 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | HTR6, NPY5R, NPY2R | OPRM1 46/4885HTR6 1/4885L3MBTL3 4675/4885 |
| US-20070060581-A1 | 1-Sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands | HTR6, HTR1A, HTR1F | OPRM1 71/4885HTR6 1/4885L3MBTL3 4588/4885 |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | OPRM1 64/4885HTR6 1/4885L3MBTL3 4500/4885 |
| US-20070185158-A1 | Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | HTR6, SLC6A4, HTR4 | OPRM1 196/4885HTR6 1/4885L3MBTL3 4155/4885 |
| US-20070043041-A1 | Indol-6 sulfonamide derivative, their preparation and their use 5-ht-6 as modulators | HTR6, TPH1, TPH2 | OPRM1 124/4885HTR6 1/4885L3MBTL3 1948/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | OPRM1 46/4885HTR6 1/4885L3MBTL3 4675/4885 |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | OPRM1 39/4885HTR6 4/4885L3MBTL3 4610/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | OPRM1 45/4885HTR6 2/4885L3MBTL3 4693/4885 |
| US-20070185207-A1 | Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | HTR6, HTR7, TPH1 | OPRM1 110/4885HTR6 1/4885L3MBTL3 4463/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | OPRM1 4558/4885HTR6 1173/4885L3MBTL3 2290/4885 |
| US-20070032520-A1 | Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | HTR6, HTR5A, TPH1 | OPRM1 93/4885HTR6 1/4885L3MBTL3 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.